INBXInhibrx Biosciences, Inc.
$95.10+245% 1Y
$95.10
$27.1252 weeks$141.84
The financials
Inhibrx Biosciences, Inc. by the numbers
Inhibrx Biosciences, Inc. (INBX) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026), down 100% from the same quarter a year earlier. That came with net loss of $37M. For the full year FY2025, revenue was $1.3M (+550% year on year) and net income −$140M. The next results filing is expected around Nov 13, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $0 | $1.3M | to a loss |
| Operating income | −$32M | −$27M | n/a |
| Net income | −$37M | −$29M | n/a |
| Diluted EPS | −$2.34 | −$1.85 | n/a |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $0.00
License grew -100% year on year
Segment Latestyear on year
- License$0.00$0.00year on year -100%-100%
On our screens:Most shorted stocks
Biotechnology
The closest names by size in the same industry